Building a leading microbiome company in oncology

We restore and modulate patient-microbiome symbiosis
to improve survival in cancer.

Key Figures

4

clinical trials in oncology

3

products in development

13

patent families filed

Our vision

We want to become the undisputed leader in delivering Microbiome Ecosystem Therapies to treat moderate to severe dysbiosis in patients by mastering different modalities.

Our mission

We aim to develop, commercialize, and license innovative Microbiome medicines for patients with severe oncology diseases, using our full ecosystem modalities, on a global basis.

Our team

Siân Crouzet

Chief Operations Officer

Siân joined MaaT Pharma in 2016 as a CFO. She is now COO/CFO and focuses on the finances and general operations management at the company. In the past, she held various finance roles, including 7 years as Principal Financial Officer and Director at Avadel Pharmaceuticals (AVDL) where she was involved in a capital raise of $130 million. Siân started her career at EY.

CPA, IFRS Certified

Savita Bernal

Chief Business Officer

Savita joined MaaT Pharma in May 2020 as Chief Business Officer. Prior to joining the company, Savita was the Director of Strategic Marketing and Corporate Communications, Business Development at ADOCIA. She held various roles in Business Development and Marketing at e(ye)BRAIN, a medical device company dedicated to the early diagnosis of neurological disease and worked as a Consultant for the Healthcare Industry at E&Y.

PhD in neuroscience, MBA

Hervé Affagard

CEO and co-founder

Hervé Affagard is the CEO and co-founder of MaaT Pharma. For the past 15 years, Hervé has been an intra/entrepreneur in the healthcare industry, after starting his career in IT in the steel industry. In late 2014, Hervé co-founded the company alongside Dr. Joël Doré, author of nearly 500 publications, and
one of the world's most cited authors in the microbiome sphere today, after a professional career that spanned multiple industries. Hervé has led MaaT Pharma’s development from its early concept in 2013 and has been at the forefront of the development of the microbiome healthcare ecosystem in France and Europe. In January 2022, Hervé has been elected President of Allliance Promotion Microbiote, an organization founded in 2021 to support the microbiome sector development in France.

Engineer, MBA

Isabelle Adeline

Chief Of Staff

Isabelle joined the MaaT Pharma in November 2020 as Chief of Staff. She is in charge of special projects to support the CEO based on strategic priorities, as well as the Quality and IP teams. Isabelle brings more than 25 years of experience in the pharmaceutical industry. Prior to joining MaaT Pharma, Isabelle had been an independent consultant for Institut Pasteur and SmartImmue, VP Operations as Voisin Consulting and held several executive positions at GSK and Bristol-Myers Squibb.

Pharm D, MBA

Carole Schwintner

Chief Technology Officer

Carole is the Chief Technology Officer at MaaT Pharma and has led MaaT Pharma’s pharmaceutical development activities since 2014. She brings 20 years of experience in the pharmaceutical industry, having previously held multiple responsibilities in cGMP manufacturing at Biorad and has been in charge of operations for a start-up company specializing in glycosylated proteins. She is the co-author of 7 published patents and 7 scientific publications.

PhD in microbiology, Engineer in Agronomy, Genetics and Biotechnology

Our Scientific Advisory Board

Dr. Ernst Holler

MD, PhD

Dr. Ernst Holler was Director of the Clinical and Experimental Allogeneic Stem Cell Transplant Program in the Department of Internal Medicine at the University of Regensburg, Germany, for more than 20 years and is now Senior Professor on Translational Research in GvHD.

With more than 250 peer-reviewed manuscripts to his name, he is an expert in the field of Graft-vs-Host-Disease and was awarded the Van Bekkum Award, the highest award from the European Society for Stem Cell Transplantation.

Dr. Florent Malard

MD, PhD

Dr. Florent Malard is a hematologist at the Hospital Saint-Antoine and an Associate Professor at Sorbonne University in Paris, France. His research interests were clinical and translational studies on allogeneic hematopoietic stem cell transplantation, with a particular focus on preclinical studies on graft-versus-host disease. He joined Dr. van den Brink’s laboratory to study thymopoiesis reconstitution after thymic injury, particularly after allogeneic hematopoietic stem cell transplantation.
His research includes clinical and translational studies on allogeneic hematopoietic stem cell transplantation with a particular focus on preclinical studies on GvHD and has published over 100 peer-reviewed manuscripts.

Pr. Mohamad Mohty

Medical Hematology – Oncology Advisor

Doctor Mohamad Mohty is Professor of Haematology, and head of the Haematology and Cellular Therapy Department at the Saint-Antoine Hospital and Sorbonne University (Paris, France). He also leads a translational research team (INSERM team) at the Saint-Antoine Research Center, Paris, France. He. Over the past 25 years or so, Professor Mohty, an active member of the EBMT, has always been a key figure of the EBMT and in the stem cell transplant and cellular therapy field. He has published over 600 peer-reviewed articles internationally and lectured in more than 70 countries.
In 2021, Professor Mohty has been nominated a “Chevalier de la Légion d’Honneur”, the highest French award, and one of the world’s most widely recognized decorations.

MD, PhD

Pr. Hassane Zarour

MD, PhD

Professor of Medicine, Immunology and Dermatology at University of Pittsburgh School of Medicine, Pr. Zarour is a Cancer Immunologist with a long-lasting interest in cancer immunotherapies, cancer vaccines and human T cell immunology. His research focuses on immunotherapies of melanoma, T cell responses to melanoma antigens and on the mechanisms of melanoma-induced T cell dysfunction. He has made seminal contributions in the field of human cancer immunology, identifying multiple novel tumor antigen-specific CD4 epitopes, and determining the role of the novel inhibitory receptor pathways Tim-3 and TIGIT in impeding T cell responses to melanoma. Most recently, he has initiated translational studies evaluating the role of the gut microbiome in regulating clinical responses to PD-1 blockade in melanoma, including a first-in-human clinical trial to evaluate the safety and efficacy of fecal microbiota transplant (FMT) obtained from long-term PD-1 responder patients and pembrolizumab in PD-1 refractory melanoma patients. As a co-leader of the of the Cancer Immunology and Immunotherapy Program (CIIP), he will contribute to its mission, and together with basic and clinical investigators, foster the translation of novel laboratory findings into novel immunotherapy of cancers.

Co-Leader of the Melanoma and Skin Cancer SPORE
Co-Leader Cancer Immunology and Immunotherapy Program

Pr. Eric Pamer

MD, PhD

Pr. Eric Pamer, a Donald F. Steiner Professor, Departments of Medicine, Microbiology, and Pathology and Director, Duchossois Family Institute, focuses his research on the impact of the intestinal microbiota on resistance to Vancomycin-resistant Enterococcus faecium, Clostridium difficile and Klebsiella pneumoniae infections in patients receiving cancer treatment, with a specific focus on highly immunocompromised patients undergoing allogeneic hematopoietic stem cell transplantation.

Dr. Robert Zeiser

Prof. Dr.

Prof. Dr. Robert Zeiser is Head of the Tumor Immunology and Immune Modulation at the Medical Center of the University of Freiburg in Germany. His research and treatment focus on acute leukemia, malignant melanoma, tumor cell migration, allogeneic hematopoietic stem cell transplantatio, and functional imaging. Professor Zeiser is the winner of the Artur Pappenheim Prize 2014 of the German Society for Hematology and Medical Oncology (DGHO) and the Richtenhain Prize 2016 of the German Cancer Research Center.

Dr. Joël Doré

Scientific Advisor

Joël is a worldwide renowned researcher with more than 200 publications relating to the Host/Microbiome interaction. Joël Doré is a research director in the Joint Research Unit for Food and Gut Microbiology for Human Health and scientific director of the MetaGenoPolis, both of which are part of INRA Île-de-France – Jouy-en-Josas and brings more than 30 years of research in the Microbiome field. Now one of the most cited scientists in the world (HiCiSci), he began his research on animals.

PhD

Dr. Robert Jenq

MD

Dr. Jenq is currently an assistant professor at MD Anderson Cancer Center, in the Departments of Genomic Medicine and Stem Cell Transplantation. His research aims to improve outcomes for patients undergoing hematopoietic cell transplantation, with a particular focus on the intestinal microbiota and how changes in the composition of intestinal bacterial commensals can impact on clinical outcomes.
MD

Dr. Jonathan Peled

MD, PhD

Dr. Peled is a medical oncologist at the Memorial Sloan Kettering Cancer Center. Dr Peled specializes in bone marrow transplantation for blood cancers including leukemias, multiple myeloma, myelodysplastic syndrome, and lymphoma.

He studies how the intestinal microbiota interact with the host immune system as it relates to hematopoietic stem-cell transplantation, with a particular interest in graft-vs-tumor activity and graft-vs-host disease.

His long-term research goals include developing microbiota-based biomarkers that will be clinically useful in the care of transplant recipients, as well as microbiota-targeted therapeutic strategies to improve patient outcomes.

Pr. Franck Carbonnel

MD, PhD

Franck Carbonnel, MD, PhD, is a professor of Gastroenterology at the Université Paris Saclay since 2008. and the head of the Gastroenterology Department at the University Hospital
of Kremlin Bicêtre (Assistance Publique-Hôpitaux de Paris). He is specialized in inflammatory bowel disease care and research (clinical, epidemiological and translational). He is also
involved in care of patients with enterocolitis due to immune-checkpoint inhibitors and contributed to their description. He recently investigated the role of intestinal microbiota to predict response and intestinal toxicity of immune checkpoint inhibitors.

MD, PhD

Our Board of Directors

Jean-Marie Lefevre

Chairman of the Board – Non-Executive Director

Jean-Marie has been President and CEO of Biocodex. He steered the creation of the “Biocodex Microbiota Institute” supporting innovative projects from Microbiota researchers. Jean-Marie has a long-track record of CEO positions amongst international firms such as LVMH or Bongrain.

Engineering degree Ecole Centrale Paris, MBA from Insead

Dorothée Burkel

Non-Executive Independant Director

Dorothée Burkel holds a Master's degree from the Institut d'Etudes Politiques in Paris and is an independent director on the board of Directors. She is also Director of Human Resources, Information Systems and Communication and a member of the Executive Committee of PartnerRe. She brings decades of high-level experience in human resources and communication, having participated in the transformation of companies at an international level in the new technology and financial sectors.
She was formerly HR Director EMEA at Google and HR Director France at AOL.

Chief Corporate and People Operations Officer

Muriel Prudent

Non-Executive Director

Muriel Prudent is an Investor at Bpifrance, French public investment bank, managing a portfolio of health- and other deeptech startups within the PSIM Fund, which focuses on major tech disruptions.
Graduated from HEC Paris and Bocconi University in Milan.

Hervé Affagard

CEO and co-founder

Hervé Affagard is the CEO and co-founder of MaaT Pharma. For the past 15 years, Hervé has been an intra/entrepreneur in the healthcare industry, after starting his career in IT in the steel industry. In late 2014, Hervé co-founded the company alongside Dr. Joël Doré, author of nearly 500 publications, and
one of the world's most cited authors in the microbiome sphere today, after a professional career that spanned multiple industries. Hervé has led MaaT Pharma’s development from its early concept in 2013 and has been at the forefront of the development of the microbiome healthcare ecosystem in France and Europe. In January 2022, Hervé has been elected President of Allliance Promotion Microbiote, an organization founded in 2021 to support the microbiome sector development in France.

Engineer, MBA

Jean Volatier

Non-Executive Independant Director

Jean Volatier is a graduate of the Magistère en Sciences de Gestion de l'Universtité Paris IX Dauphine (PSL), of the D.E.S.C.F. and of the Master en Executive Mangement Globale RSE de Mines Paris Tech (PSL) and is an independent director on the Board of Directors. Jean Volatier is currently CFO at Inventiva. Prior to that, he started his career at Pricewaterhouse Coopers in Paris and Philadelphia. He then moved to different positions in the Finance Department, first at Laboratoires URGO Soins & Santé and then internationally at Laboratoires Fournier, before holding different positions as CFO at the Soufflet and NAOS groups.

CFO

Dr. Claude Bertrand

Non-Executive Independant Director

Claude joined MaaT Pharma as an independant board member in July 2020. Since 2017, Claude has held the position of Executive Vice President of R&D and Chief Scientific Officer at Servier. He brings decades of high-level leadership in pharmaceutical R&D, having previously served as Executive Vice-President of R&D at Ipsen Pharma and as Global Senior Vice President for Respiratory & Inflammation Research Area at AstraZeneca. His career also includes senior positions at Novartis, Roche and Pfizer.

PharmD, PhD

Isabelle de Crémoux

Non-Executive Director

Isabelle de Crémoux is CEO and Managing Partner of Seventure Partners and leads the Life Sciences team. She joined Seventure in 2001 to establish the Life Sciences division. Isabelle supervises the Life Sciences business and personally invests in French and Scandinavian and north American biotech, nutrition, healthcare, personalized medicine. Isabelle has a particular interest in the microbiome field and frequently gives lectures at conferences in this domain. As a visionary, she launched Health for Life Capital™, the first European investment vehicule to support the microbiome revolution. Prior to joining Seventure Partners, she worke at Arthur Andersen/ EY, Pfizeer and Laboratoires Fournier.

Engineering degree from Ecole Centrale Paris

Our history

  • 2014

    Incorporation of MaaT Pharma, based on INRAE technology

  • 2015

    In vitro and preclinical validation

    +70% Reconstruction of the gut microbiota achieved, dose determination

  • 2016

    Inauguration of the first GMP- compliant platform

    €10 Million Serie A Financing Round

    Proof of Concept Study (ODYSSEE) First AML patient treated with autologous FMT

  • 2017

    Development of high richness and diversity pooled products

    Partnerships with Biocodex and Bioaster

  • 2018

    Initiation of Phase II (HERACLES): MaaT013 in steroid refractory gastro-intestinal aGVHD patients after Allogenic HSCT

    ODYSSEE Study showed 90% reconstruction in 25 patients

    Proprietary medical device system received CE mark

  • 2019

    Patent Portfolio expansion with 3 granted patents

    MaaT013 Initial Early Access Program (EAP) data presented at ASH (n=8)

  • 2020

    Series B completed

    Additional EAP data presented (n=29)

    Initiation of Phase I (CIMON): MaaT033 in hematology malignant Patients Under intensive Chemotherapy

    Partnership with AP-HP

  • 2021


    Announced positive HERACLES data

    Additional promising EAP data presented at ASH (n=52)

    Several positive DSMB decisions for CIMON

    Listed on Euronext Paris - ticker MAAT

  • 2022

    MaaT033: positive interim engraftment data - Phase 1b trial

    Partnership with Skyepharma to establish the first exclusive Microbiome Ecosystem Therapies cGMP manufacturing facility in France

    Hervé Affagard, CEO of MaaT Pharma, is elected President of Alliance Promotion Microbiote,the association federating the French major players in the microbiome industry

    MaaT013: Initiation of Phase 3 trial (ARES) in patients with aGvHD,the first Phase 3 trial globally for a microbiome-based therapy in haemato-oncology

    Initiation of Phase 2a trial sponsored by AP-HP (PICASSO) evaluating MaaT013 in combination with Immune Checkpoint Inhibitors for patients with melanoma